(Press-News.org) Petrovax announced today the positive results from “Long-CoV-III-21,” a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer in adult patients with pulmonary sequelae of COVID-19. Bovhyaluronidase azoximer, marketed under the brand name Longidaza, is a polymer-conjugated hyaluronidase with an extended half-life. The study drug and placebo were administered for 71 days, with an observation period extending to Day 180.
Longidaza demonstrated a statistically significant 62% reduction in the proportion of patients with exertional desaturation (OR = 0.35, p = 0.0051) and a 27% reduction in the proportion of patients exhibiting exertional dyspnea (OR = 0.62, p = 0.043) by Day 71 compared to placebo. Marked improvements were also observed in resting dyspnea and distance walked during the six-minute walk test. The drug's effects on exercise tolerance indicators were sustained for more than 100 days after the last dose.
Longidaza did not affect pulmonary function in the overall population. However, subgroup analysis revealed that the drug was associated with a significantly greater change from baseline in predicted Forced Vital Capacity (FVC) in patients with cardiovascular comorbidities (difference = 3.31%, p = 0.042) and in those infected with earlier variants of SARS-CoV-2 (difference = 4.17%, p = 0.021) compared to placebo.
“Long-CoV-III-21 is among the first randomized, double-blind trials to show a significant effect of a novel therapy in patients with post-COVID pulmonary sequelae. The sustained effects of Longidaza offer hope for patients struggling with dyspnea, fatigue, and reduced physical capacity to improve their quality of life,” said Sergey Avdeev, MD, Chair of the Pulmonology Department at Sechenov University and principal investigator of the trial. “Although the drug did not show a significant effect on pulmonary function recovery in the entire study population, results in subgroups strongly suggest that research into hyaluronidase-based medications should continue—not only for post-COVID pulmonary sequelae but also for other fibrotic conditions.”
Study findings were presented at the Asian Pacific Society of Respirology congress in Hong Kong.
In parallel with long COVID research, Petrovax has been developing an inhaled form of Longidaza for the treatment of interstitial lung diseases. The safety of this new delivery route was demonstrated in a recent Phase 1 study. A Phase 2 trial of inhaled Longidaza in patients with idiopathic pulmonary fibrosis is planned for 2025.
About Long-CoV-III-21
Long-CoV-III-21 is a prospective, randomized, double-blind, placebo-controlled clinical trial designed to test the efficacy and safety of Longidaza (3000U) intramuscular injections in patients with pulmonary sequelae of COVID-19 (NCT06383819). Three hundred ninety-two patients were randomized 1:1 to receive either Longidaza or placebo every 5 days for 71 days. The follow-up period lasted up to Day 180. The study enrolled patients with a history of COVID-19 infection 1 to 12 months prior to screening, restrictive lung disease, fibrotic-like radiological abnormalities in the lungs, and decreased SpO2 at rest or after exertion. The study was conducted at 37 clinical sites.
The primary endpoint was the change from baseline in predicted Forced Vital Capacity.
The main secondary endpoints included the proportions of patients with exertional desaturation and dyspnea after the six-minute walk test, the distance walked in the six-minute walk test, and dyspnea at rest.
About Long COVID and Pulmonary Sequelae of COVID-19
Long COVID affects a significant portion of COVID-19 patients, with studies estimating its prevalence at approximately 10-20% of those infected. Long COVID impacts several organ systems, leading to a variety of symptoms, including persistent fatigue, breathlessness, and exercise intolerance, which can last for months or even years beyond the initial infection. A subset of patients with long COVID develop pulmonary sequelae, characterized by fibrotic-like changes in the lungs (assessed by CT), respiratory symptoms, and restrictive-type pulmonary function impairment. Currently, these patients are treated with antifibrotics, steroids, immunosuppressant medications and n-acetyl cysteine. However, all of these approaches lack high-quality evidence specific to post-COVID pulmonary sequelae.
“It may seem that we are past COVID-19, but a recent CDC survey shows that 7% of U.S. adults have had long COVID—about 17 million people. Developing effective therapies to help patients recover is crucial,” says Sergey Avdeev.
About Hyaluronic Acid and Longidaza
Recent research shows that hyaluronic acid is not only a structural component of the extracellular matrix but also a key regulator of fibrotic tissue remodeling and chronic inflammation — key mechanisms of post-COVID pulmonary sequelae. Longidaza (bovhyaluroniodaze azoximer) is a polymer-conjugated hyaluronidase with over 20 years of clinical use, a well-established safety profile, and a prolonged half-life. It has been used clinically as an anti-inflammatory and anti-adhesion therapy. Preclinical studies have demonstrated Longidaza’s potential to reduce fibrosis, while a pilot study involving 160 post-COVID-19 patients showed statistically significant improvements in pulmonary function, respiratory symptoms, and exercise tolerance.
END
Bovhyaluronidaze azoximer significantly reduces exercise intolerance in patients with long-term pulmonary sequelae of COVID-19
2024-12-12
ELSE PRESS RELEASES FROM THIS DATE:
New insights into the evolution and paleoecology of mosasaurs: most comprehensive study to date
2024-12-12
Mosasaurs are extinct marine lizards, spectacular examples of which were first discovered in 1766 near Maastricht in the Netherlands, fueling the rise of the field of vertebrate palaeontology (the study of fossil remains of animals with backbones). Palaeontologist Michael Polcyn presented the most comprehensive study to date on the early evolution and ecology of these extinct marine reptiles. On 16 December, Polcyn will receive his PhD from Utrecht University for his research into the evolution of the mosasaurs. "Mosasaurs are a textbook example of macroevolution, ...
New insights into brain mechanisms underlying empathy
2024-12-12
Genova (Italy), 12th December 2024 – A specific brain mechanism modulates how animals respond empathetically to others’ emotions. This is the latest finding from the research unit Genetics of Cognition, led by Francesco Papaleo, Principal Investigator at the Istituto Italiano di Tecnologia (IIT - Italian Institute of Technology) and affiliated with IRCCS Ospedale Policlinico San Martino in Genova. The study, recently published in Nature Neuroscience, provides new insights into psychiatric ...
Semiconductor device technology recognized by the "Olympics of Semiconductors"
2024-12-12
The Korea Institute of Materials Science (KIMS) announced that Dr. Yong-Hun Kim from the Energy & Environment Materials Research Division and Dr. Kyung Song from the Material Characterization Center, in collaboration with Professor Hyun-Sang Hwang's team from POSTECH, have successfully developed a groundbreaking heterojunction technology. This technology integrates tungsten disulfide (WS₂), a two-dimensional (2D) material, with hafnium zirconium oxide (HZO), a ferroelectric material, achieving both interfacial stability and superior crystallinity. The results have been accepted by the International Electron Devices Meeting 2024 (IEDM 2024), ...
What brings richness to sparkling wines?
2024-12-12
“Rich” and “full-bodied” are terms that people often use to describe the taste of wine. They are also the properties that kokumi compounds bring to foods like mature Gouda cheese, though scientists haven’t widely explored them in wines. In ACS’ Journal of Agricultural and Food Chemistry, researchers now connect the dots and report 11 probable kokumi compounds in sparkling wines.
Kokumi is often confused with the better-known term umami. Umami is a savory, meaty flavor and is one of the basic five tastes, along with sweet, ...
Towards room-temperature superconductivity: Insights into optical properties of bi-based copper-oxide superconductors
2024-12-12
Superconductors are materials which conduct electricity without any resistance when cooled down below a critical temperature. These materials have transformative applications in various fields, including electric motors, generators, high-speed maglev trains, and magnetic resonance imaging. Among these materials, CuO2 superconductors like Bi2212 stand out due to their high critical temperatures that surpass the Bardeen–Cooper–Schrieffer limit, a theoretical maximum temperature limit for superconductivity. However, ...
World’s smallest molecular machine: reversible sliding motion in ammonium-linked ferrocene
2024-12-12
Artificial molecular machines, nanoscale machines consisting of a few molecules, offer the potential to transform fields involving catalysts, molecular electronics, medicines, and quantum materials. These machines operate by converting external stimuli, like electrical signals, into mechanical motion at the molecular level. Ferrocene, a special drum-shaped molecule composed of an iron (Fe) atom sandwiched between two five-membered carbon rings, is a promising foundational molecule for molecular machinery. Its discovery earned the Nobel Prize in Chemistry in 1973, and it has since ...
Researchers reveal key factors behind Japan’s plastic waste removal rates in rivers
2024-12-12
Plastic pollution is an ever-growing problem in today’s world, as most societies have become overly dependent on plastics for packaging, medical supplies, and general goods. Plastic litter accumulation in the ocean, either through deliberate dumping or by being transported from a river, poses significant environmental challenges. Additionally, this plastic eventually degrades into small fragments called microplastics, which then impact diverse marine and land ecosystems by working their way up the food chain and into most living organisms. Though their negative effects on cell health are still under study, many nations have taken a cautionary stance, ...
Implantable sensors are helping scientists improve injury recovery
2024-12-12
EUGENE, Ore. — Dec. 12, 2024 — Tiny implantable sensors are helping University of Oregon researchers optimize the process of recovery from severe bone injuries.
Scientists at the UO’s Phil and Penny Knight Campus for Accelerating Scientific Impact have developed miniature implantable sensors that transmit real-time data about what’s happening at an injury site. In a new study, they use the technology to show that a resistance-training rehabilitation program can significantly improve femur injuries in rats ...
Improved predictive accuracy of fusion plasma performance by data science
2024-12-12
Fusion energy research is being pursued around the world as a means of solving energy problems. Magnetic confinement fusion reactors aim to extract fusion energy by confining extremely hot plasma in strong magnetic fields. Its development is a comprehensive engineering project involving many advanced technologies, such as superconducting magnets, reduced-activation materials, and beam and wave heating devices. In addition, predicting and controlling the confined plasma, in which numerous charged particles and electromagnetic fields interact in complex ...
Common brain network links brain atrophy patterns seen in schizophrenia
2024-12-12
A new study led by investigators from Mass General Brigham has identified a unique brain network that links varied patterns of brain atrophy, or shrinkage, associated with schizophrenia. By combining neuroimaging data from multiple studies involving more than 8,000 participants, the research team found a specific connectivity pattern of atrophy that was present across different stages and symptoms of schizophrenia — and distinct from brain networks associated with other psychiatric disorders. The findings will help to guide a clinical trial that will start recruiting patients soon and will ...